Hillaire-Buys D, Peyriere H, Lobjoie E, Bres J, Ossart M, Despaux E
Laboratoire de Pharmacologie, Faculté de Médecine, Hôpital Arnaud de Villeneuve, Montpellier, France.
Br J Clin Pharmacol. 1995 Jul;40(1):95-7. doi: 10.1111/j.1365-2125.1995.tb04543.x.
The pharmacokinetics of teicoplanin infused for 30 min at a dose of 6 mg kg-1 was studied in 11 infected patients under continuous arterio-venous haemofiltration (CAVH). Serum teicoplanin levels were assayed by h.p.l.c. over 24 h. After 0.5 h, i.e. at the end of the infusion, the mean plasma concentration was 49.6 +/- 15.1 mg l-1. At the last sampling time (24 h), the mean concentration was 2.6 +/- 1.0 mg l-1. The concentration of teicoplanin was determined in the haemofiltrates. The percentage of the administered dose recovered in the haemofiltrate was low: less than 1% for seven patients, between 1.8 and 3.7% for three patients and 7% for one patient. CAVH patients should be given teicoplanin using the same dosage regimens as previously described for patients with renal impairment.
在11例接受持续动静脉血液滤过（CAVH）的感染患者中，研究了以6 mg kg-1的剂量输注30分钟替考拉宁的药代动力学。通过高效液相色谱法（h.p.l.c.）在24小时内测定血清替考拉宁水平。0.5小时后，即输注结束时，平均血浆浓度为49.6±15.1 mg l-1。在最后一个采样时间点（24小时），平均浓度为2.6±1.0 mg l-1。测定了血液滤过液中替考拉宁的浓度。血液滤过液中回收的给药剂量百分比很低：7例患者低于1%，3例患者在1.8%至3.7%之间，1例患者为7%。CAVH患者应使用先前描述的肾功能损害患者的相同给药方案给予替考拉宁。
